Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation.

Abstract:

:Two hundred and ten bronchoalveolar lavage (BAL) samples were obtained from 50 patients 10 days before and on defined days after allogeneic bone marrow transplantation (BMT). The samples were examined for human cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-6) by polymerase chain reaction (PCR). Fifteen patients (30%) had a positive result for HCMV in at least one sample and 25 (50%) were positive for HHV-6 in at least one sample. Five patients developed HCMV-associated interstitial pneumonia (HCMV-IP) within 100 days after allogeneic BMT. Four of these patients were positive for both HCMV and HHV-6. Conspicuous HHV-6 positivity was detected in BAL samples obtained because of respiratory symptoms. No association was found between detection of HHV-6 and acute graft-versus-host disease. Engraftment failure or a delay in engraftment was observed in none of the 50 patients. The data from this study indicate that HHV-6 is a pathogen in HCMV-associated, as well as in non-HCMV-associated infectious lung disease after BMT.

journal_name

Bone Marrow Transplant

authors

Buchbinder S,Elmaagacli AH,Schaefer UW,Roggendorf M

doi

10.1038/sj.bmt.1702569

subject

Has Abstract

pub_date

2000-09-01 00:00:00

pages

639-44

issue

6

eissn

0268-3369

issn

1476-5365

journal_volume

26

pub_type

杂志文章
  • Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.

    abstract::We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Katsanis E,Xu Z,Anderson PM,Dancisak BB,Bausero MA,Weisdorf DJ,Blazar BR,Ochoa AC

    更新日期:1994-10-01 00:00:00

  • Management of acquired aplastic anemia in children.

    abstract::The diagnosis of aplastic anemia in children requires exclusion of a variety of inherited or acquired BM failure syndromes with similar phenotypes. An efficient diagnostic plan is important because time from diagnosis to 'final' treatment is directly related to outcome regardless of the therapeutic option chosen. The ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2012.235

    authors: Korthof ET,Békássy AN,Hussein AA

    更新日期:2013-02-01 00:00:00

  • Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia.

    abstract::Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/s41409-018-0154-0

    authors: Yahng SA,Park SS,Jeon YW,Yoon JH,Shin SH,Lee SE,Cho BS,Eom KS,Kim YJ,Lee S,Min CK,Kim HJ,Cho SG,Kim DW,Min WS,Lee JW

    更新日期:2018-10-01 00:00:00

  • Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells.

    abstract::Six patients treated for relapsed chronic myeloid leukaemia after allogeneic bone marrow transplantation with donor buffy coat transfusions were investigated. In the 5 patients who achieved molecular remission high frequencies of host-reactive interleukin 2-secreting T helper cell precursors (Th-p) were detectable by ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bunjes D,Theobald M,Hertenstein B,Wiesneth M,Novotny J,Arnold R,Heimpel H

    更新日期:1995-05-01 00:00:00

  • Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma.

    abstract::Repeated high-dose (HD) chemotherapy with peripheral blood stem cell (PBSC) transplantation is a new modality aimed at increasing both the dose and its intensity in the treatment of chemosensitive tumours. The aim of this study was to evaluate the tolerance, pharmacokinetics (PK) and pharmacodynamics (PD) of HD single...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1702806

    authors: Vassal G,Tranchand B,Valteau-Couanet D,Mahé C,Couanet D,Schoeppfer C,Grill J,Kalifa C,Hill C,Ardiet C,Hartmann O

    更新日期:2001-03-01 00:00:00

  • Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma.

    abstract::Relapsed disease remains a major obstacle following autologous haematopoietic SCT (HSCT) for non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Studies regarding the importance of detectable tumour cells in PBSC collections have been inconclusive. Patients undergoing autologous HSCT for NHL and MM between 2001 an...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2008.318

    authors: Ho J,Yang L,Banihashemi B,Martin L,Halpenny M,Atkins H,Sabloff M,McDiarmid SA,Huebsch LB,Bence-Bruckler I,Giulivi A,Allan DS

    更新日期:2009-02-01 00:00:00

  • Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

    abstract::Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2015.205

    authors: Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

    更新日期:2016-01-01 00:00:00

  • Peripheral blood stem cell mobilization with granulocyte colony-stimulating factor and a harvesting procedure in pediatric donors.

    abstract::The safety of injecting healthy donors with granulocyte colony-stimulating factor (G-CSF) has not been established. To evaluate PBSC mobilization and harvesting efficacy in the pediatric population, we compared it with those in adult donors. In this study, we conclude that PBSC mobilization and harvesting protocol in ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Kawano Y,Takaue Y,Watanabe T,Watanabe A,Iwai A,Kuroda Y

    更新日期:1998-06-01 00:00:00

  • Unrelated donor marrow transplantation in children: transplant policy and outcome in Leiden Paediatrics SCT-Centre.

    abstract::The transplant policy for unrelated donor (UD) BMT at Leiden Paediatrics' SCT-Centre consisted of the use of (1) fully HLA-matched donors or, if not available, HLA-class I matched and/or cytotoxic T-lymphocyte precursor (CTLp)-negative donors and (2) protective isolation of the recipient and antimicrobial suppression ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.104

    authors: Vossen JM,Donker AE,Heemskerk MB,Lie JL,van Weel-Sipman MH,Bredius RG,Bakker JD,Egeler RM,Oudshoorn M

    更新日期:2010-01-01 00:00:00

  • A two-phase pathogenesis of graft-versus-host disease in mice.

    abstract::Activation of donor T cells is required for the development of graft-versus-host disease (GVHD), a major complication of bone marrow transplantation. We investigated a murine model of GVHD across major and minor histocompatibility barriers. BALB/c recipients were lethally irradiated and transplanted with 10(7) bone ma...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703328

    authors: van Leeuwen L,Guiffre A,Atkinson K,Rainer SP,Sewell WA

    更新日期:2002-01-01 00:00:00

  • Hematopoietic stem cell transplantation activity in Europe 1999.

    abstract::This survey on transplantation of hematopoietic stem cells from blood or bone marrow in Europe, the 10th in a series, reports the numbers of transplants performed in 1999 and concentrates on changes in indications and donor types. Members of the European Group for Blood and Marrow Transplantation and associated teams ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702995

    authors: Gratwohl A,Passweg J,Baldomero H,Urbano-Ispizua A,European Group for Blood and Marrow Transplantation (EBMT).

    更新日期:2001-05-01 00:00:00

  • PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.

    abstract::Acute myeloid leukemia (AML) is an immune-susceptible malignancy, as demonstrated by its responsiveness to allogeneic stem cell transplantation (alloSCT). However, by employing inhibitory signaling pathways, including PD-1/PD-L1, leukemia cells suppress T cell-mediated immune attack. Notably, impressive clinical effic...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-0966-6

    authors: van Ens D,Mousset CM,Hutten TJA,van der Waart AB,Campillo-Davo D,van der Heijden S,Vodegel D,Fredrix H,Woestenenk R,Parga-Vidal L,Jansen JH,Schaap NPM,Lion E,Dolstra H,Hobo W

    更新日期:2020-12-01 00:00:00

  • Mesenchymal stem cells: heading into the clinic.

    abstract::In recent years, there has been an increasing interest in non-hematopoietic pluripotent progenitor cells that are found in the bone marrow. Mesenchymal stem cells (MSCs) are the first non-hematopoietic progenitors to be isolated from the bone marrow and extensively characterized. In addition to their ability to suppor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1702791

    authors: Koç ON,Lazarus HM

    更新日期:2001-02-01 00:00:00

  • First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (

    abstract::Thalidomide-dexamethasone therapy was given in patients (<61 years) with previously untreated symptomatic multiple myeloma. The aim of this study was to assess the efficacy and toxicity of this combination as first-line therapy, and to determine its effect on stem cell collection and engraftment. During first-line the...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究,收录出版

    doi:10.1038/sj.bmt.1705050

    authors: Abdelkefi A,Torjman L,Ben Romdhane N,Ladeb S,El Omri H,Ben Othman T,Elloumi M,Bellaj H,Lakhal A,Jeddi R,Aissaouï L,Saad A,Hsaïri M,Boukef K,Dellagi K,Ben Abdeladhim A

    更新日期:2005-08-01 00:00:00

  • Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005.

    abstract::Over more than three decades, The Anthony Nolan Trust (ANT) has provided an unrelated donor (UD) for over 4000 children and adults lacking a suitable family member donor, and has remained at the forefront of developments in haematopoietic stem cell transplantation (HSCT) and bone marrow register management. These thre...

    journal_title:Bone marrow transplantation

    pub_type:

    doi:10.1038/sj.bmt.1705365

    authors: Duarte RF,Pamphilon D,Cornish J,Shaw BE,Samson D,Craddock C,Marks D,Mufti GJ,Powles RL,Apperley JF,Madrigal JA,Goldman JM

    更新日期:2006-05-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

    abstract::The Janus-activated kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is effective in decreasing symptomatic splenomegaly and myelofibrosis (MF)-related symptoms. However, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option. We evaluated the impact of ruxolitinib on the outcome after HCT....

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.173

    authors: Jaekel N,Behre G,Behning A,Wickenhauser C,Lange T,Niederwieser D,Al-Ali HK

    更新日期:2014-02-01 00:00:00

  • High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.

    abstract::Forty-eight adult patients with recurrent or refractory intermediate grade or immunoblastic lymphoma received high-dose carmustine (BCNU), etoposide, Ara C and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (BMT). Median follow-up is 906 days (range 613-2067 days). The complete remission r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: van Besien K,Tabocoff J,Rodriguez M,Andersson B,Mehra R,Przepiorka D,Dimopoulos M,Giralt S,Suki S,Khouri I

    更新日期:1995-04-01 00:00:00

  • Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Acc

    abstract::These updated EBMT guidelines review the clinical evidence, registry activity and mechanisms of action of haematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) and other immune-mediated neurological diseases and provide recommendations for patient selection, transplant technique, follow-up and fut...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0684-0

    authors: Sharrack B,Saccardi R,Alexander T,Badoglio M,Burman J,Farge D,Greco R,Jessop H,Kazmi M,Kirgizov K,Labopin M,Mancardi G,Martin R,Moore J,Muraro PA,Rovira M,Sormani MP,Snowden JA,European Society for Blood and Marrow Tr

    更新日期:2020-02-01 00:00:00

  • European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

    abstract::We have retrospectively analyzed the impact of prognostic factors on the outcome of serologically HLA-matched unrelated donor (UD) BMT for CML. For this purpose, we have studied a cohort of 366 patients transplanted in Europe between January 1985 and December 1994. The median age of the 211 males and 155 females was 3...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700844

    authors: Devergie A,Apperley JF,Labopin M,Madrigal A,Jacobsen N,Carreras E,Prentice HG,Jouet JP,Kolb HJ,Herstenstein B,Bacigalupo A,Evensen SA,Ljungman P,de Witte T,Reiffers J,Nagler A,Clark RE,Goldman JM,Gratwohl A

    更新日期:1997-07-01 00:00:00

  • Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.

    abstract::Invasive fungal infections (IFIs) are major complications after allogeneic hematopoietic SCT (HSCT). PCR-based assays able to detect fungal DNA have been reported to precede clinical diagnosis of IFI. We performed a prospective study to evaluate a PCR-based pre-emptive approach. Ninety-nine patients undergoing reduced...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/bmt.2010.38

    authors: Blennow O,Remberger M,Klingspor L,Omazic B,Fransson K,Ljungman P,Mattsson J,Ringdén O

    更新日期:2010-12-01 00:00:00

  • G-CSF in an infant donor: a method of reducing harvest volume in bone marrow transplantation.

    abstract::We report the case of a 4-year-old female with high-risk ALL in first CR who received a BMT from an 11-month-old matched sibling treated with G-CSF in order to obtain an adequate number of mononuclear cells in a limited volume of bone marrow. The absence of toxicity, efficacy of the procedure and quality of the post-t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Pession A,Locatelli F,Prete A,Pigna A,Magrini E,Conte R,Rosito P,Paolucci G

    更新日期:1996-03-01 00:00:00

  • Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes.

    abstract::Thirty-five patients with myelodysplastic syndromes (MDS) were treated with BMT between 1986 and 1994. Their median age was 41 years (range 23-60). Thirteen patients had transfusion-dependent refractory anaemia (RA). Twenty-two patients suffered from more advanced stages of MDS, 15 being in complete remission (CR) aft...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700739

    authors: Mattijssen V,Schattenberg A,Schaap N,Preijers F,De Witte T

    更新日期:1997-04-01 00:00:00

  • Thrombotic microangiopathy following allogeneic bone marrow transplantation.

    abstract::Thrombotic microangiopathy is one of the complications of bone marrow transplantation and is related to other complications such as graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, and cytomegalovirus infection. Thrombotic microangiopathy occurred in three out of 12 patients who underwen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701890

    authors: Takatsuka H,Takemoto Y,Okamoto T,Fujimori Y,Tamura S,Wada H,Okada M,Kanamaru A,Kakishita E

    更新日期:1999-08-01 00:00:00

  • Cord blood stem cell transplantation for Diamond-Blackfan anemia.

    abstract::Bone marrow transplantation has been successfully employed in the treatment of Diamond-Blackfan anemia (DBA). Transplantation with bone marrow stem cells involves, however, considerable treatment-related toxicity, partially in the form of GVHD. Through the use of cord blood stem cells it may be possible to reduce the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700675

    authors: Vettenranta K,Saarinen UM

    更新日期:1997-03-01 00:00:00

  • Characterization of CD34+ subsets derived from bone marrow, umbilical cord blood and mobilized peripheral blood after stem cell factor and interleukin 3 stimulation.

    abstract::We characterized CD34+ cells purified from bone marrow (BM), mobilized peripheral blood (PB) and cord blood (CB) and we tried to establish correlations between the cell cycle kinetics of the CD34+CD38- and CD34+CD38+ subpopulations, their sensitivity to SCF and IL-3 and their expression of receptors for these two CSFs...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702145

    authors: De Bruyn C,Delforge A,Lagneaux L,Bron D

    更新日期:2000-02-01 00:00:00

  • Peripheral blood stem cell (PBSC) collection in extremely low-weight infants.

    abstract::While PBSC collection has become a safe procedure for adults, only a few reports exist about its efficacy, safety and feasibility in paediatric patients, especially extremely low-weight infants. We describe successful PBSC collection in three infants of less than 10 kg body weight (BW; range: 6.92-9.4 kg) suffering fr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Nussbaumer W,Schönitzer D,Trieb T,Fink FM,Maurer-Dengg K,Höcker P,Wagner A,Schwaighofer H,Nachbaur D,Niederwieser D

    更新日期:1996-07-01 00:00:00

  • Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years.

    abstract::Invasive fungal infections (IFI) with substantial mortality constitute an increasing problem among BMT patients. From 1986 to 1996 148 children underwent BMT, and are included in a retrospective analysis of the incidence, risk factors and outcome of IFI. By histopathology or culture-proven IFI (Candida, 10; Aspergillu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702654

    authors: Hovi L,Saarinen-Pihkala UM,Vettenranta K,Saxen H

    更新日期:2000-11-01 00:00:00

  • Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.

    abstract::The human recombinant G-CSF filgrastim has been widely used for the mobilization of CD34(+) stem cells of healthy donors (HD). In 2008, the G-CSF biosimilar XM02 (Ratiograstim, Tevagrastim and Biograstim) was approved by the European Medicines Agency (EMA) for the mobilization of PBSC. However, there is limited experi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2012.270

    authors: Schmitt M,Xu X,Hilgendorf I,Schneider C,Borchert K,Gläser D,Freund M,Schmitt A

    更新日期:2013-07-01 00:00:00

  • Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

    abstract::In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2015.286

    authors: Robinson SP,Boumendil A,Finel H,Blaise D,Poiré X,Nicolas-Virelizier E,Or R,Malladi R,Corby A,Fornecker L,Caballero D,Pohlreich D,Nagler A,Thieblemont C,Finke J,Bachy E,Vincent L,Schroyens W,Schouten H,Dreger P

    更新日期:2016-03-01 00:00:00

  • Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization.

    abstract::Plerixafor augments PBSC collection, but the optimal approach for incorporating it into mobilization is uncertain. Forty-nine consecutive patients mobilized with G-CSF alone were analyzed, and a day 4 peripheral blood CD34(+) cell count of 0.015/ml was found to predict for a day 5 apheresis yield of 2 × 10(6) CD34(+) ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.74

    authors: Chen AI,Bains T,Murray S,Knight R,Shoop K,Bubalo J,Fowler C,Slater S,Maziarz RT

    更新日期:2012-12-01 00:00:00